Sana Biotechnology (SANA), a clinical-stage biotech company specializing in gene and cell therapies, has recently experienced significant moves in its stock performance, attracting investor attention. On Jan. 8, the stock soared close to 162% after the company announced positive news from its cell therapy targeting Type 1 diabetes, which it claims to be a “potentially life-changing cure.”
Last year, the stock fell 55%, while the S&P 500 Index ($SPX) rose 27.6%. However, 2025 has been a prosperous year for the company. SANA stock is up 120% year-to-date, compared to a 0.71% dip in the broader market.
